Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 18  |  Issue : 2  |  Page : 352--361

Synergistic effect of growth factor receptor-bound protein 2/epidermal growth factor receptor dual-targeting peptide inhibitor and salinomycin on osteosarcoma


Zuochong Yu1, Yanlong Xu3, Longhai Du3, Fan Zhang2, Minghao Shao2, Lin Xie2, Guoping Cai4, Feizhou Lyu2 
1 Department of Orthopedics, Huashan Hospital of Fudan University; Department of Orthopedics, Jinshan Hospital of Fudan University, Shanghai, China
2 Department of Orthopedics, Huashan Hospital of Fudan University, Shanghai, China

Correspondence Address:
Feizhou Lyu
No. 12, Middle Wulumuqi Road, Shanghai 200040
China
Guoping Cai
No. 1508, Longhang Road, Shanghai 201508
China

Context: The growth factor receptor-bound protein 2 (Grb2)-Sos1 interaction, mediated by modular domains, plays an essential role in the oncogenic MAPK signaling pathway in osteosarcoma (OS). Recently, a dual-targeting peptide that targets the epidermal growth factor receptor and Grb2-Src homology 3 domain in OS cells was designed and synthesized. Aims: We investigated the synergistic effects of the peptide and salinomycin (Sal), a chemotherapeutic drug with effective anti-OS properties in clinical therapy. Subjects and Methods: Flow cytometry was used to measure the targeting efficacy of the peptide. Migration and CCK-8 assays were used to explore whether Sal and the peptide could synergistically inhibit OS cell behavior. Western blotting was used to detect apoptosis. Statistical Analysis Used: Data were analyzed using the GraphPad Prism 5.01. Statistical analysis was performed using the Student's t-test for the direct comparisons and one-way analysis of variance for the comparisons among the multiple groups. Statistical significance was set at P < 0.05. Results: The peptide was shown to target OS cells. When applied together, Sal and the peptide synergistically inhibited OS cell migration, invasion, and proliferation through the inhibition of Grb2-Sos1. This synergistic treatment also promoted the apoptosis of OS cells and inhibited tumor volume in vivo. Conclusions: These data provide valuable insights into the molecular mechanisms of OS and may be beneficial in clinical therapy.


How to cite this article:
Yu Z, Xu Y, Du L, Zhang F, Shao M, Xie L, Cai G, Lyu F. Synergistic effect of growth factor receptor-bound protein 2/epidermal growth factor receptor dual-targeting peptide inhibitor and salinomycin on osteosarcoma.J Can Res Ther 2022;18:352-361


How to cite this URL:
Yu Z, Xu Y, Du L, Zhang F, Shao M, Xie L, Cai G, Lyu F. Synergistic effect of growth factor receptor-bound protein 2/epidermal growth factor receptor dual-targeting peptide inhibitor and salinomycin on osteosarcoma. J Can Res Ther [serial online] 2022 [cited 2022 Aug 20 ];18:352-361
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2022;volume=18;issue=2;spage=352;epage=361;aulast=Yu;type=0